# Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

> **NCT05501054** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Ciforadenant

## Key facts

- **NCT ID:** NCT05501054
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-09
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05501054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05501054, "Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05501054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*